Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed · Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma that has not responded to previous therapy.

Key facts

Study ID

NCT00019487

Run by

National Cancer Institute (NCI)

Starts

1998-11-01

Expected to finish

2003-05-01

Last updated by the study team

2013-06-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.